PROSPECTUS
SHEFFIELD PHARMACEUTICALS, INC.
2,893,334 SHARES OF COMMON STOCK
This Prospectus relates to the offer and resale by certain selling
stockholders (collectively, the "Selling Stockholders") of (i) 2,333,334 shares
(the "Debenture Conversion Shares") of common stock, $.01 par value ("Common
Stock"), of Sheffield Pharmaceuticals, Inc. (the "Company") issuable upon
conversion of the Company's 6% Convertible Subordinated Debentures Due September
22, 2000 (the "Convertible Debentures"), (ii) 420,000 shares of Common Stock
issuable as interest payable in lieu of cash interest on Convertible Debentures
and (iii) 140,000 shares of Common Stock issuable upon the exercise of certain
stock purchase warrants of the Company originally issued to the purchasers of
Convertible Debentures (the "Debenture Warrants"). This Prospectus also relates,
pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended
(the "Securities Act"), to the offer and resale by certain Selling Stockholders
of an indeterminate number of shares of Common Stock that may become issuable by
reason of the anti-dilution provisions of the aforementioned securities and an
indeterminate number of shares of Common Stock issuable upon conversion of
Convertible Debentures and in lieu of cash interest payable thereon resulting
from the fluctuating conversion rate of the Convertible Debentures that is
determined based upon the market price of the Company's publicly-traded Common
Stock as of the date of the applicable conversion thereof. See "Description of
Securities - 6% Convertible Subordinated Debentures."
The Common Stock presently trades on the American Stock Exchange (the
"AMEX") under the symbol "SHM". On December 5, 1997, the closing sale price of
the Common Stock on the AMEX was $1.625.
The Selling Stockholders, directly or through broker-dealers, may sell
the Common Stock offered hereby from time to time on the AMEX or on any other
securities exchange on which Common Stock is listed or in privately negotiated
transactions, at fixed prices that may be changed, at market prices prevailing
at the time of sale, at prices related to such prevailing market prices or at
privately negotiated prices. The Selling Stockholders and any underwriters,
brokers, dealers or agents that act in connection with the sale may be deemed to
be "underwriters" within the meaning of the Securities Act and any commissions
received by them and any profit on the resale of securities as principal might
be deemed to be underwriting discounts under the Securities Act. The Company has
agreed to indemnify the Selling Stockholders and certain other persons against
certain liabilities, including liabilities under the Securities Act. See "Plan
of Distribution."
THE SECURITIES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK.
THE COMPANY EXPECTS TO INCUR ADDITIONAL OPERATING LOSSES
OVER THE NEXT SEVERAL YEARS WHICH RAISES SUBSTANTIAL
DOUBT ABOUT ITS ABILITY TO CONTINUE AS A
GOING CONCERN. SEE "RISK FACTORS" AT PAGES 9 - 14 BELOW.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION NOR HAS THE COMMISSION OR ANY STATE SECURITIES
COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS
PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY
IS A CRIMINAL OFFENSE.
<PAGE>
No underwriting commissions or discounts will be paid by the Company in
connection with this offering. Estimated expenses payable by the Company in
connection with the offering are $105,000. The aggregate proceeds to the Selling
Stockholders from the sale of the Common Stock will be the purchase price of the
Common Stock sold less the aggregate agents' commissions and underwriters'
discounts, if any, and other expenses of issuance and distribution not borne by
the Company. See "Plan of Distribution."
No person has been authorized to give any information or to make any
representations in connection with this offering other than those contained in
this Prospectus and, if given or made, such other information and
representations must not be relied upon as having been authorized by the
Company. Neither the delivery of this Prospectus nor any sale made hereunder
shall, under any circumstances, create any implication that there has been no
change in the affairs of the Company since the date hereof or that the
information contained herein is correct as of any time subsequent to its date.
This Prospectus does not constitute an offer to sell or a solicitation of an
offer to buy any securities other than the registered securities to which it
relates. This Prospectus does not constitute an offer to buy such securities in
any circumstances in which such offer or solicitation is unlawful.
The date of this Prospectus is December 5, 1997.
-2-
<PAGE>
TABLE OF CONTENTS
PAGE
----
AVAILABLE INFORMATION........................................................4
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE..............................4
THE COMPANY..................................................................6
RISK FACTORS.................................................................9
USE OF PROCEEDS.............................................................14
DIVIDEND POLICY.............................................................15
RECENT DEVELOPMENTS.........................................................15
SELLING STOCKHOLDERS........................................................16
DESCRIPTION OF SECURITIES...................................................17
PLAN OF DISTRIBUTION........................................................18
LEGAL MATTERS...............................................................19
EXPERTS.....................................................................19
ADDITIONAL INFORMATION......................................................20
-3-
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in
accordance therewith files reports, proxy statements and other information with
the Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information can be inspected and copied at the public
reference facilities maintained by the Commission at Room 1024, Judiciary Plaza,
450 Fifth Street, N.W., Washington, D.C. 20549 and at the Regional Offices of
the Commission at Seven World Trade Center, 13th Floor, New York, New York 10048
and Northwestern Atrium Center, 500 West Madison Street, Chicago, Illinois
60611. Copies of such material can be obtained from the Public Reference Section
of the Commission at Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C.
20549, at prescribed rates. Such material may also be accessed electronically by
means of the Commission's home page on the Internet at http://www.sec.gov. In
addition, reports, proxy statements and other information concerning the Company
can be inspected and copied at the offices of the AMEX at 86 Trinity Place, New
York, New York 10006, on which the Common Stock of the Company is listed for
trading (Symbol: SHM).
The Company has filed with the Securities and Exchange Commission a
Registration Statement on Form S-3 under the Securities Act with respect to the
Common Stock offered hereby. For further information with respect to the Company
and the securities offered hereby, reference is made to the Registration
Statement. Statements contained in this Prospectus as to the contents of any
contract or other document are not necessarily complete, and in each instance,
reference is made to the copy of such contract or document filed as an exhibit
to the Registration Statement, each such statement being qualified in all
respects by such reference.
----------------------
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Company incorporates by reference the following documents
heretofore filed with the Commission pursuant to the Exchange Act:
(a) Annual Report of the Company on Form 10-KSB for the
fiscal year ended December 31, 1996, as amended by
Amendment Nos. 1 and 2 filed with the Commission on
April 16, 1997 and July 30, 1997, respectively.
(b) Quarterly Report of the Company on Form 10-Q for the
quarterly period ended March 31, 1997 as filed with
the Commission, as amended by Amendment No. 1 filed
with the Commission on July 31, 1997.
(c) Quarterly Report of the Company on Form 10-Q for the
quarterly period ended June 30, 1997 as filed with
the Commission.
(d) Quarterly Report of the Company on Form 10-Q for the
quarterly period ended September 30, 1997 as filed
with the Commission.
(e) The description of the Common Stock and other matters
set forth in the Company's Registration Statement on
Form 8-B filed with the Commission on July 7, 1995.
All documents filed by the Company after the date of this Prospectus
pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the
termination of this offering, are deemed to be incorporated by reference in this
Prospectus and shall be deemed to be a part hereof from the date of filing of
such documents. Any statement contained in a document incorporated by reference
in this Prospectus shall be deemed to be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein (or in any other
subsequently filed document which is also incorporated by reference in this
Prospectus) modifies or supersedes such statement. Any statement so modified or
superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Prospectus.
-4-
<PAGE>
The Company hereby undertakes to provide without charge to each person
to whom a copy of this Prospectus has been delivered, on the written or oral
request of any such person, a copy of any or all of the documents referred to
above which have been or may be incorporated in this Prospectus by reference,
other than exhibits to such documents. Written requests for such copies should
be directed to Sheffield Pharmaceuticals, Inc., 425 South Woodsmill Road, Suite
270, St. Louis, Missouri 63017, Attention: Loren G. Peterson, Chief Executive
Officer. Oral requests should be directed to Mr. Peterson at (314) 579-9899.
-5-
<PAGE>
THE COMPANY
The Company is engaged in the development of proprietary prescription
pharmaceutical products targeted at patient markets with unmet medical needs
over a range of therapeutic areas. The Company's strategy is to focus its
resources on later stage projects that have a more rapid and predictable path to
marketing approval. The Company's objective is to be a specialty pharmaceutical
company that develops and markets its own proprietary products. The principal
elements of the Company's business strategy consist of the following: (i) the
acquisition of opportunities with unrealized commercial potential that address
unmet medical needs and require only later stage development prior to regulatory
approval; (ii) a focus initially on segments of the large, rapidly growing
respiratory market, which includes certain chronic diseases requiring long-term
therapy; (iii) the development of proprietary formulations of currently approved
pharmaceutical compounds, which can reduce regulatory and development risks
typically associated with the development of new chemical entities; (iv) the
management of the clinical development and regulatory approval of its products
that will be performed by clinical research organizations or organizations with
similar development capabilities; (v) the contracting for the manufacture of its
products by pharmaceutical manufacturers with a history of producing cost
effective, high quality, U.S. Food and Drug Administration ("FDA") compliant
products; and (vi) the marketing of its products directly through the Company's
specialty sales force that will be built at such time as opportunities warrant.
As of the date of this Prospectus, the Company has acquired certain
development and marketing rights in the following technologies:
MULTI-DOSE INHALER (MSI). The Company holds exclusive worldwide license
rights to a multi-dose inhaler of Siemens AG (the "MSI Inhaler"). The MSI
Inhaler is a drug delivery system that allows for the administration of a range
of drugs to the lungs for asthma, chronic obstructive pulmonary disease and
other respiratory diseases. In addition, the MSI Inhaler's delivery system may
find application in the treatment of non-respiratory illnesses that may be
treated by drug deliveries to the lungs. The Company plans to develop drug
formulations for use with the MSI Inhaler.
ION PHARMACEUTICALS, INC. TECHNOLOGIES. The Company, through Ion
Pharmaceuticals, a Delaware corporation and a wholly-owned subsidiary of the
Company ("Ion"), holds exclusive worldwide license rights to certain compounds
and their uses for the treatment of conditions characterized by unregulated cell
proliferation or cell growth and sickle cell anemia (collectively, the "Ion
Pharmaceuticals Technologies"). Ion's intellectual property portfolio consists
of clotrimazole, its metabolites, and a number of proprietary new chemical
entities co-owned by Ion termed the Trifens(TM). Such compounds have
demonstrated promise in therapeutic applications for treating a number of
conditions characterized by unregulated cell proliferation, such as cancer
(including multiple drug resistant cancer) and certain dermatological
conditions, as well as sickle cell anemia and secretory diarrhea.
RBC-CD4 ELECTROINSERTION TECHNOLOGY. The Company is the worldwide
licensee of certain technology (the "RBC-CD4 Electroinsertion Technology")
relating to the electroinsertion of full-length CD4 protein into the red blood
cell membrane ("RBC-CD4") for use as a therapeutic in the treatment of the human
immunodeficiency virus ("HIV") that leads to Acquired Immune Deficiency Syndrome
("AIDS"). The electroinsertion process inserts CD4, the protein that serves as
the binding site of the HIV virus, into red blood cells. This altered cell
complex acts as a decoy and is designed to cleanse the blood of infection by
binding to and removing the HIV virus from circulation before it can infect
other cells in the human immune system. The related Phase I/IIA clinical trial
was conducted by The Johns Hopkins University Medical Center.
LIPOSOME-CD4 TECHNOLOGY. The Company is the worldwide licensee of
certain technology (the "Liposome- CD4 Technology") relating to the
incorporation of CD4 antigens into liposome bilayers and their use as a
therapeutic agent in the treatment of HIV and AIDS. While RBC-CD4
Electroinsertion Technology is being developed by the Company to target HIV and
HIV-infected cells in the blood, Liposome-CD4 Technology is being developed by
the
-6-
<PAGE>
Company's exclusive sublicensee, Sequus Pharmaceuticals, to target infections in
the human lymphatic system, a major reservoir for infection not reached by blood
circulation.
HIV/AIDS VACCINE. The Company holds an exclusive worldwide license to a
potential HIV/AIDS vaccine and diagnostic developed by Professor Jean-Claude
Chermann, one of the original Pasteur Institute discoverers of HIV. The vaccine
concept developed by Professor Chermann utilizes a cellular antigen that is
incorporated into the membrane surface of HIV after the HIV virus has reproduced
buds from infected cells. This cellular antigen does not appear to vary across
the various strains of the virus and may provide a stable target to develop
antibodies that can prevent infection. The Company believes this approach may
also protect against both blood-born and sexual transmission of HIV. The
Company's goal is to develop an oral formulation that would make the vaccine
potentially less costly and easier to distribute to a broad population.
UGIF TECHNOLOGY. The Company holds an exclusive worldwide license to a
potential prostate cancer therapy. The related technology focuses on a
urogenital sinus derived growth inhibitory factor that may inhibit the growth of
transformed cells and tumors in the human prostate. The related research has
been conducted by scientific and medical investigators affiliated with Baylor
College of Medicine and headed by Dr. David R. Rowley.
MEMBRANE ATTACK COMPLEX (MAC)/COMPLEMENT TECHNOLOGY. The Company holds
exclusive worldwide license rights to certain membrane attack complex
(MAC)/complement technology relating to the loading of therapeutic and
diagnostic molecules into cells. Through the use of certain complement proteins,
pores or channels can be formed in various cell membranes, allowing a pathway
for the entry of molecules of various sizes into such cells. This technology
could provide for the selective delivery of various therapeutic and diagnostic
agents to target, I.E., cancer cells or viruses. The related research has been
conducted by scientific and medical investigators affiliated with Harvard
Medical School and headed by Dr. Jose Halperin.
The Company's research and development of its technologies are at
various stages of progress. The Company's research and development activities to
date have not resulted in a commercial product. Most of the Company's
technologies are at early stages of research and development and are at least
several years away from receiving FDA approval or from commercialization.
Management currently believes its MSI Inhaler will be its first technology to
receive FDA approval, which approval is currently estimated to be received in
approximately three to four years. However, there can be no assurance that any
of the Company's technologies will receive final approval from the FDA or will
result in a commercialized product.
The table below indicates (i) the Company's direct research and
development expenses by project for the nine months ended September 30, 1997,
for the fiscal year ended December 31, 1996 and from the Company's inception to
September 30, 1997, (ii) the Company's current estimate by project of committed
and/or anticipated funding requirements after September 30, 1997 and (iii)
revenues received to date by project.
-7-
<PAGE>
DIRECT RESEARCH AND DEVELOPMENT
EXPENSES
(IN DOLLARS)
<TABLE>
<CAPTION>
COMMITTED
AND/OR
NINE ANTICIPATED
MONTHS FISCAL YEAR R&D FUNDING
ENDED ENDED INCEPTION TO AFTER REVENUE
R&D PROJECT 9/30/97 12/31/96 9/30/97 9/30/97* RECEIVED
- ---------------------------- ------------- --------------- ------------------ ------------------ ------------
<S> <C> <C> <C> <C> <C>
Multi-Dose Inhaler (MSI) 154,504 144,409 1,617,127 15,102,000 -0-
Ion Pharmaceuticals, 220,528 2,097,020 4,819,711 93,000 10,000
Inc. Technologies
RBC-CD4 Electroinsertion -0- 515,036 6,254,185 -0- -0-
Technology
Liposome-CD4 Technology -0- 60,449 2,322,322 -0- 500,000
HIV/AIDS Vaccine 12,500 414,849 1,211,618 137,500 -0-
UGIF Technology 20,018 16,398 223,437 20,000 -0-
Membrane Attack Complex 60,936 121,874 365,618 -0- -0-
(MAC)/Complement
Technology
</TABLE>
- ------------------------------
* These amounts constitute management's estimate of anticipated direct
R&D expenses as of the date of this Prospectus. The amounts and rate of
application of the Company's funds to any particular project are
expected to fluctuate and will depend in part on the Company's
successful completion of various stages of research, the availability
of additional financing and the Company's identification and
acquisition of rights in new technologies in the future.
The Company is a party to license agreements pursuant to which the
Company has obtained worldwide exclusive licenses to its technologies. Each of
these license agreements require the Company to pay the licensors royalties on
proceeds received by the Company from the commercialization of related products.
The royalty rates payable by the Company under these license agreements
generally range from 3.75% to 50% of gross compensation received by the Company
in respect of related commercialized product. These license agreements also
require the Company to develop the related technology and grant the Company the
right, under certain circumstances, to sublicense the related technologies. In
addition, the Company is a party to a sublicense agreement with Sequus
Pharmaceuticals, Inc. ("Sequus") pursuant to which the Company has granted
Sequus an exclusive sublicense to develop and commercialize its Liposome CD-4
Technology. The sublicense agreement requires Sequus to pay the Company
royalties in varying amounts on proceeds received by Sequus in connection with
commercialization of the related technology by Sequus. The amount of interest
that the Company will maintain in a particular technology is a factor of the
amount of net income retained by the Company after payment of royalties payable
by the Company to the related technology licensor and any related third party
contractors (E.G., research institutions or private companies) and the amount of
royalties received by the Company from any sublicensees of the technology, which
retained amount of interest will vary among each of the Company's technologies.
The Company was organized under Canadian law in October 1986 as
Sheffield Strategic Metals, Inc. The Company commenced operations in the United
States in January 1992. Effective May 19, 1992, Sheffield Pharmaceuticals, Inc.
became domesticated as a Wyoming corporation without reincorporation pursuant to
a "continuance" procedure under Wyoming corporation law. On June 13, 1995, the
Company changed its state of incorporation to Delaware by means of a merger with
and into a newly-formed wholly-owned Delaware subsidiary of the Company. Such
merger and the resulting change of the Company's state of incorporation to
Delaware was approved by the Company's stockholders in January 1995. The Company
-8-
<PAGE>
changed its name from "Sheffield Medical Technologies Inc." to "Sheffield
Pharmaceuticals, Inc." effective June 27, 1997. Unless the context otherwise
indicates, the "Company" as used herein means Sheffield Pharmaceuticals, Inc.,
its predecessors and its wholly-owned subsidiaries Ion and CP Pharmaceuticals,
Inc.
The Company's headquarters are located at 425 South Woodsmill Road,
Suite 270, St. Louis, Missouri 63017 and its telephone number is (314) 579-9899.
RISK FACTORS
THE SECURITIES OFFERED HEREBY ARE HIGHLY SPECULATIVE AND PROSPECTIVE
PURCHASERS SHOULD BE AWARE THAT THE PURCHASE OF SUCH SECURITIES INVOLVES A HIGH
DEGREE OF RISK. IN ADDITION TO OTHER INFORMATION IN THIS PROSPECTUS, THE
FOLLOWING FACTORS SHOULD BE CONSIDERED CAREFULLY IN EVALUATING THE COMPANY
BEFORE PURCHASING THE SECURITIES OFFERED HEREBY. THIS PROSPECTUS CONTAINS
FORWARD- LOOKING STATEMENTS WHICH INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S
ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE
FORWARD-LOOKING STATEMENTS AS A RESULT OF CERTAIN FACTORS, INCLUDING THOSE SET
FORTH IN THE FOLLOWING RISK FACTORS AND ELSEWHERE IN THIS PROSPECTUS.
DEVELOPMENT STAGE COMPANY; HISTORY OF OPERATING LOSSES AND ACCUMULATED DEFICIT;
GOING CONCERN OPINION
The Company is in the development stage. The Company commenced its
biotechnology operations in the United States in January 1992 through a
wholly-owned subsidiary to acquire, develop and commercialize what it believed
to be promising medical technologies. On January 10, 1996, Ion was formed as a
wholly-owned subsidiary of the Company. At that time, Ion acquired the Company's
rights to the Company's anti-proliferative technology. The Company has been
principally engaged to date in research funding and licensing efforts, and has
experienced significant operating losses. The Company experienced operating
losses of $7,008,889 and $7,978,323 for the fiscal year ended December 31, 1996
and for the nine months ended September 30, 1997, respectively, and as of
September 30, 1997, the Company had an accumulated deficit of $34,680,075. The
independent auditors' report dated February 12, 1997, except for Note 9 as to
which the date is March 14, 1997, on the Company's consolidated financial
statements stated that the Company has generated only minimal operating revenue,
has incurred recurring operating losses and requires additional capital and that
these conditions raise substantial doubt about its ability to continue as a
going concern. The Company expects that it will continue to have a high level of
operating expenses and will be required to make significant up-front
expenditures in connection with license and development agreements with
independent companies, universities and other institutions for research and
development and product development activities. As a result, the Company
anticipates significant additional operating losses for 1997 and that such
losses will continue thereafter until such time, if ever, as the Company is able
to generate sufficient revenues to sustain its operations.
The Company's ability to achieve profitable operations is dependent in
large part on regulatory approvals of its products and technologies and on its
ability to enter into manufacturing and marketing agreements with other
pharmaceutical, biomedical or medical companies. There can be no assurance that
the Company will ever achieve profitable operations.
SIGNIFICANT LIQUIDITY RESTRAINTS
The Company's cash available for funding its operations as of September
30, 1997 was $1,005,106. As of such date, the Company had trade payables and
accrued liabilities of $797,001, current research obligations of $135,037 and
other liabilities of $144,487. In addition, the Company is obligated to fund
between September 30, 1997 and September 30, 1998 approximately $1,850,000 in
the
-9-
<PAGE>
aggregate under existing agreements. The Company will be required to obtain
additional funds for its business through operations or equity or debt
financings, collaborative arrangements with corporate partners or from other
sources. No assurance can be given that these funds will be available for the
Company to finance its development on acceptable terms, if at all. If adequate
funds are not available from operations or additional sources of funding, the
Company's business will suffer a material adverse effect. As of the date of this
Prospectus there were 25,500 shares of the Company's Series A Cumulative
Convertible Redeemable Preferred Stock (the "Series A Preferred Stock") issued
and outstanding. The Series A Preferred Stock is redeemable by holders for $125
per share in the event of (i) any reclassification or change of outstanding
shares of Common Stock issuable upon Conversion of Series A Preferred Stock
(other than a change in par value), (ii) any consolidation or merger to which
the Company is a party other than a merger in which the Company is the
continuing corporation and which does not result in any reclassification of, or
certain changes in, outstanding shares of Common Stock or (iii) any sale or
conveyance of all or substantially all of the property or business of the
Company as an entirety. In addition, upon the occurrence of certain changes of
control, Series A Preferred Stock holders may redeem their shares of Series A
Preferred Stock for an amount per share equal to the greater of (a) $125 and (b)
the product of the aggregate number of shares of Common Stock into which a share
of Series A Preferred Stock is otherwise convertible on the date preceding the
change of control multiplied by the then current market price of a share of
Common Stock.
NEED FOR ADDITIONAL FINANCING
Since the Company does not expect to generate substantial revenues from
the sale of any products or technologies in the immediate future, the Company
will require substantial additional funds from other sources to complete its
research and development, to conduct additional clinical tests and to establish
manufacturing and marketing relationships with pharmaceutical, biomedical or
medical companies. The Company will attempt to acquire funds for these purposes
through operations, additional equity or debt financings, collaborative
arrangements with corporate partners or from other sources. Management estimates
that, based on the status of the Company's current projects, the Company will
require $8,000,000 to satisfy its cash requirements for research and development
and $3,100,000 to satisfy its cash requirements for general and administrative
costs during the next twelve months. The Company is currently in discussions
with various parties that may be interested in providing the Company with
financing but, as of the date of this Prospectus, no commitment has been
received from potential sources of additional funding. No assurance can be given
that these funds will be available for the Company to finance its development on
acceptable terms, if at all. If adequate funds are not available from operations
or additional sources of funding, the Company's business will suffer a material
adverse effect.
LONG TERM DEVELOPMENT OF TECHNOLOGIES; NO COMMERCIALIZATION OF PRODUCTS TO DATE
The Company has not yet begun to generate revenues from the sale of
products or technologies. The Company is funding research that began, in some
cases, many years before the Company acquired rights in such projects. The
Company's products and technologies will require significant additional
development, laboratory and clinical testing and investment prior to
commercialization. The Company does not expect regulatory approval for
commercial sales of any of its products or technologies in the immediate future.
There can be no assurance that such products or technologies will be
successfully developed, prove to be safe and efficacious in clinical trials,
meet applicable regulatory standards, obtain required regulatory approvals, be
capable of being produced in commercial quantities at reasonable costs or be
successfully commercialized and marketed.
-10-
<PAGE>
ROYALTY PAYMENT OBLIGATIONS
The owners and licensors of the technology rights acquired by the
Company are entitled to receive up to 50% of all royalties and payments in lieu
of royalties received by the Company from commercialization, if any, of products
in respect of which the Company holds licenses. Accordingly, in addition to its
substantial investment in research and development of technologies, the Company
will be required to make substantial payments to others in connection with
revenues derived from commercialization of products, if any, in respect of which
the Company holds licenses. Consequently, the Company will not receive the full
amount of any revenues that may be derived from commercialization of products
derived from the Company's technologies to fund ongoing operations.
POTENTIAL LOSS OF RIGHTS UPON DEFAULT
Under the terms of existing agreements, the Company is obligated to
make periodic installments to finance research and development activities
according to specified budgets. The Company is obligated to fund approximately
$1,850,000 in the aggregate under existing agreements during the twelve-month
period following September 30, 1997. In the event that the Company defaults in
the payment of an installment under the terms of an existing licensing
agreement, its rights thereunder could be forfeited. As a consequence, the
Company could lose all rights under a license agreement to the related licensed
technology, notwithstanding the total investment made through the date of the
default. There can be no assurance that unforeseen obligations or contingencies
will not deplete the Company's financial resources and, accordingly, the
Company's resources may not be available to fulfill the Company's commitments.
DEPENDENCE ON PRINCIPAL INVESTIGATORS
The Company is dependent upon the active participation of its principal
investigators in the advancement of the research and development associated with
their related projects. The loss of a principal investigator, particularly in
the early stages of the development of a technology, could have a material
adverse effect on the related project and the Company's prospects. To date, the
Company has not suffered the loss of any of its principal investigators on any
projects that are under active development.
RAPID TECHNOLOGICAL CHANGE; COMPETITION
The medical research field is subject to rapid technological change and
innovation. Pharmaceutical and biomedical research and product development are
rapidly evolving fields in which developments are expected to continue at a
rapid pace. Reports of progress and potential breakthroughs are occurring with
increasing frequency. There can be no assurance that the Company will have a
competitive advantage in its fields of technology or in any of the other fields
in which the Company may concentrate its efforts.
The Company's success will depend upon its ability to develop and
maintain a competitive position in the research, development and
commercialization of products and technologies in its areas of focus.
Competition from pharmaceutical, chemical, biomedical and medical companies,
universities, research and other institutions is intense and is expected to
increase. All, or substantially all, of these competitors have substantially
greater research and development capabilities, experience, and manufacturing,
marketing, financial and managerial resources. Further, acquisitions of
competing companies by large pharmaceutical or other companies could enhance
such competitors' financial, marketing and other capabilities. There can be no
assurance that developments by others will not render the Company's products or
technologies obsolete or not commercially viable or that the Company will be
able to keep pace with technological developments.
-11-
<PAGE>
GOVERNMENT REGULATION
The Company's ongoing research and development projects are subject to
rigorous FDA approval procedures. The preclinical and clinical testing
requirements to demonstrate safety and efficacy in each clinical indication (the
specific condition intended to be treated) and regulatory approval processes of
the FDA can take a number of years and will require the expenditure of
substantial resources by the Company. Delays in obtaining FDA approval would
adversely affect the marketing of products to which the Company has rights and
the Company's ability to receive product revenues or royalties. Moreover, even
if FDA approval is obtained, a marketed product, its manufacturer and its
manufacturing facilities are subject to continual review and periodic
inspections by the FDA, and a later discovery of previously unknown problems
with a product, manufacturer or facility may result in restrictions on such
product or manufacturer. Failure to comply with the applicable regulatory
requirements can, among other things, result in fines, suspensions of regulatory
approvals, product recalls, operating restrictions and criminal prosecution.
Additional government regulation may be established which could prevent or delay
regulatory approval of the Company's products. Sales of pharmaceutical products
outside the United States are subject to foreign regulatory requirements that
vary widely from country to country. Even if FDA approval has been obtained,
approval of a product by comparable regulatory authorities of foreign countries
must be obtained prior to the commencement of marketing the product in those
countries. The time required to obtain such approval may be longer or shorter
than that required for FDA approval. The Company has no experience in
manufacturing or marketing in foreign countries nor in matters such as currency
regulations, import-export controls or other trade laws. To date, the Company
has not received final regulatory approval from the FDA or any other comparable
foreign regulatory authority in respect of any product or technology. Management
currently believes that its MSI Inhaler will be its first technology to receive
final FDA approval, which approval is currently estimated to be received in
approximately three to four years; however, there can be no assurance that such
approval will be granted by the FDA.
RISKS INCIDENT TO PATENT APPLICATIONS AND RIGHTS
The Company's success will depend in part on its ability to obtain
patent protection for products and processes and to maintain trade secret
protection and operate without infringing the proprietary rights of others. The
degree of patent protection to be afforded to pharmaceutical, biomedical or
medical inventions is an uncertain area of the law. There can be no assurance
that the Company will develop or receive sublicenses or other rights related to
proprietary technology which are patentable, that any patents pending will
issue, or that any issued patents will provide the Company with any competitive
advantages or will not be challenged by third parties. Furthermore, there can be
no assurance that others will not independently duplicate or develop similar
technologies to those developed by or licensed to the Company.
The Company supports and collaborates in research conducted at
universities and other institutions. There can be no assurance that the Company
will have or be able to acquire exclusive rights to inventions or technical
information derived from such collaborations or that disputes will not arise as
to such exclusive rights or any derivative or related research programs. If the
Company is required to defend against charges of patent infringement or to
protect its own proprietary rights against third parties, substantial costs will
be incurred and the Company could lose rights to certain products and
technologies.
RELIANCE ON THIRD PARTIES; NO MARKETING OR MANUFACTURING CAPABILITIES
The Company does not intend to manufacture or market products it may
develop using its technologies. The Company will attempt to enter into
manufacturing and marketing agreements with one or more established
pharmaceutical, biomedical and medical companies for any products that are
developed. There can be no assurance that other pharmaceutical, biomedical or
-12-
<PAGE>
medical companies will be interested in the Company's products or technologies
or be willing to enter into manufacturing or marketing agreements on terms
acceptable to the Company. Further, there can be no assurance that
pharmaceutical, biomedical or other medical companies will succeed in
manufacturing and marketing the Company's products or technologies or that the
Company will derive revenues from its products or technologies.
DEPENDENCE UPON OBTAINING HEALTHCARE REIMBURSEMENT
The Company's ability to commercialize human therapeutic and diagnostic
products may indirectly depend in part on the extent to which costs for such
products and technologies are reimbursed by private health insurance or
government health programs. The uncertainty regarding reimbursement may be
especially significant in the case of newly approved products. There can be no
assurance that price levels will be sufficient to provide a return to the
Company on its investment in new products and technologies.
ADEQUACY OF PRODUCT LIABILITY INSURANCE
The use of the Company's proposed products and processes during
testing, and after approval, may entail inherent risks of adverse effects which
could expose the Company to product liability claims. Product liability claims
could have a material adverse effect on the business and financial condition of
the Company. The Company plans to obtain, and plans to require its licensees to
obtain, product liability insurance at an appropriate stage of product
development and commercialization. There can be no assurance that the Company
and its licensees will be able to maintain or obtain adequate product liability
insurance on acceptable terms or that such insurance will provide adequate
coverage against all potential claims.
VOLATILITY OF MARKET PRICE OF SECURITIES
The market price of securities of firms in the biotechnology industry
has tended to be volatile. Announcements of technological innovations by the
Company or its competitors, developments concerning proprietary rights and
concerns about safety and other factors may have a material adverse effect on
the Company's business or financial condition. The market price of the Common
Stock may be significantly affected by announcements of developments in the
medical field generally or the Company's research areas specifically. The stock
market has experienced volatility in market prices of companies similar to the
Company that has often been unrelated to the operating results of such
companies. This volatility may have a material adverse effect on the market
price of the Common Stock.
OUTSTANDING OPTIONS AND WARRANTS; DILUTION
As of September 30, 1997, the Company had reserved approximately
4,515,000 shares of Common Stock for issuance upon exercise of outstanding
options and warrants, including shares of Common Stock issuable upon the
exercise of options and warrants held by officers and directors of the Company.
The Company has filed registration statements with the Commission covering the
resale of substantially all of the shares of Common Stock underlying such
options and warrants. The exercise of options and outstanding warrants and sales
of Common Stock issuable thereunder could have a significant dilutive effect on
the market price of shares of Common Stock and could materially impair the
Company's ability to raise capital through the future sale of its equity
securities.
NO DIVIDENDS
Holders of Common Stock are entitled to receive such dividends as may
be declared by the Board of Directors of the Company. To date, the Company has
not declared or paid any dividends on its Common Stock, and the Company does not
anticipate paying cash dividends in the foreseeable future. Rather, the Company
-13-
<PAGE>
intends to apply any earnings to the expansion and development of its business.
AUTHORIZATION OF SERIES A PREFERRED STOCK
The Company's Certificate of Incorporation authorizes the issuance of
"blank check" preferred stock with such designations, rights and preferences as
may be determined from time to time by the Board of Directors, without
shareholder approval. In the event of issuance, such preferred stock could be
utilized, under certain circumstances, as a method of discouraging, delaying or
preventing a change in control of the Company and preventing shareholders from
receiving a premium for their shares in connection with a change of control.
Except for the issuance of shares of Series A Preferred Stock that occurred in
connection with the consummation of a private placement in February 1997, the
Company has no present intention to issue any shares of its preferred stock;
however, there can be no assurance that the Company will not issue additional
shares of its preferred stock in the future.
EXERCISE OF SERIES A WARRANTS AND CONVERSION OF SERIES A CUMULATIVE CONVERTIBLE
REDEEMABLE PREFERRED STOCK
As of the date of this Prospectus, there are 25,500 shares of Series A
Preferred Stock outstanding that are convertible into shares of Common Stock.
See "Selling Stockholders." Each share of Series A Preferred Stock earns a
cumulative dividend payable in shares of Common Stock at a rate per share equal
to 7.0% per annum of the original $100.00 purchase price per share of the Series
A Preferred Stock. Cumulative stock dividends on shares of Series A Preferred
Stock are payable at the time of conversion. Each share of Series A Preferred
Stock may be converted after May 29, 1997 at varying rates of conversion. The
conversion rate on Series A Preferred Stock will be adjusted, and the number of
shares beneficially owned by the holders thereof will vary, to reflect changes
in the market price of the Common Stock, stock dividends, stock splits and
certain other circumstances. For a further description of the rights of holders
of Series A Preferred Stock, see the Certificate of Designation of Series A
Cumulative Convertible Redeemable Preferred Stock filed as an exhibit to the
Company's Annual Report on Form 10-KSB for the fiscal year ended December 31,
1996. Holders of Series A Preferred Stock also hold warrants (the "Series A
Warrants") entitling such holders to acquire a total of 351,539 shares of Common
Stock at an exercise price of $3.65 per share, subject to adjustment upon the
occurrence of certain events. The exercise of Series A Warrants, the conversion
of shares of Series A Preferred Stock and the subsequent sale of such shares of
Common Stock issuable upon such exercise and conversion could have a significant
negative effect on the market price of the Common Stock and could materially
impair the Company's ability to raise capital through the future sale of equity
securities.
USE OF PROCEEDS
The Company will receive a total of $392,000 in the event that all
shares of Common Stock offered hereby that are issuable upon exercise of the
Debenture Warrants have been issued upon such exercise. The Company anticipates
that the net proceeds will be used as to fund the research and development
relating to the MSI Inhaler and for working capital and general corporate
purposes of the Company, including the possible acquisitions of rights in new
drug development opportunities. The amounts and rate of application of such net
proceeds will be subject, among other things, to successful completion of the
various stages of research of each of the Company's research projects and the
Company's identification and acquisition of rights in new technologies after the
date of this Prospectus, which amounts and rate cannot be precisely determined
at this time. Until such proceeds are fully used, the Company intends to invest
such proceeds in investment grade, short-term interest-bearing obligations or
U.S. government obligations. The Company will not receive any proceeds from the
offer and resale of the Common Stock offered hereby.
-14-
<PAGE>
DIVIDEND POLICY
Holders of Common Stock are entitled to receive such dividends as may
be declared by the Board of Directors of the Company. The Company presently
intends to retain earnings, if any, for use in its business and does not
anticipate paying dividends (other than stock dividends payable on shares of
Series A Preferred Stock) on its outstanding capital stock in the foreseeable
future. Future payments of cash dividends will depend upon the financial
condition, results of operations and capital requirements of the Company as well
as other factors deemed relevant by the Board of Directors.
RECENT DEVELOPMENTS
On April 25, 1997, Camelot Pharmacal, L.L.C., a Missouri limited
liability company ("Camelot"), merged with and into CP Pharmaceuticals, Inc., a
newly formed subsidiary of the Company. The principals of Camelot at the time of
the merger were Loren G. Peterson, Carl F. Siekmann and David A. Byron. Pursuant
to the related agreement and plan of merger, Messrs. Peterson, Siekmann and
Byron each received 200,000 shares of Common Stock. The 200,000 shares of Common
Stock were issued pursuant to the exemption from registration under Section 4(2)
of the Securities Act. Each of Messrs. Peterson, Siekmann and Byron executed
agreements in which they represented that they were "accredited investors" and
had been given the opportunity to meet with Company management and to receive
such documentation relating to the Company's operations and financial condition
as they deemed necessary. Following the consummation of the merger, each of
Messrs. Peterson, Siekmann and Byron entered into employment agreements with
Sheffield and received stock options providing each individual the right to
purchase up to 400,000 shares of Common Stock. The Company has agreed to
reimburse Messrs. Peterson, Siekmann and Byron upon the occurrence of certain
events for certain income taxes payable by them upon exercise of their stock
options in an amount of up to $250,000 per person. At the time of the merger,
Anthony B. Alphin, Jr., Bernard Laurent, Stephen Sohn and Michael Zeldin
resigned as Directors of the Company and Mr. Peterson was elected a Director of
the Company.
In May 1997, the Company reported findings from its Phase I/II clinical
trial to assess the safety and antiviral activity of a single infusion of the
Company's HIV/AIDS therapeutic, RBC-CD4. The trial, conducted in 19 HIV-infected
subjects, had as its primary objectives to confirm the previously reported long
half-life for RBC-CD4 and to measure safety and tolerability with a secondary
objective to assess activity of a single dose of RBC-CD4. Study results
confirmed the half-life of RBC-CD4 and the related safety data indicated that
RBC-CD4 was safe and well-tolerated by the HIV-infected patients. The secondary
objective of the trial was to assess the activity of two dose levels of RBC-CD4
in HIV-infected patients. The outcome measures suggest that little sustained
activity was seen from a single infusion of RBC-CD4 at either of the two doses.
The data suggests that the frequency of a positive response, when reported, was
greater at the early time points. It should be emphasized that RBC-CD4 in this
study was evaluated as a single-dose monotherapy. The Company also announced at
such time its intention to seek a partner for the RBC-CD4 technology.
On September 22, the private placement of $1,750,000 of Convertible
Debentures was consummated. The Company received net proceeds of $1,600,000 in
such private placement. See "Description of Securities - 6% Convertible
Subordinated Debentures" below.
On December 3, 1997, Ion entered into assignment and license agreements
with a subsidiary of Immutec Pharma Inc. Pursuant to these agreements, Ion
assigned and granted license rights to a series of compounds for the treatment
of cancer, Kaposi's sarcoma and actinic keratosis for which Immutec Pharma will
provide funding and management of the development program.
-15-
<PAGE>
SELLING STOCKHOLDERS
Set forth below is information at October 15, 1997 concerning the
beneficial ownership of Common Stock of each of the Selling Stockholders who are
offering shares of Common Stock in this offering.
<TABLE>
<CAPTION>
Shares Beneficially Shares to be Shares Beneficially
Owned Prior to Sold in Owned After
Offering(1)(2) Offering Offering(3)
------------------------------- -------------- --------------------------------
NAME(1) NUMBER PERCENT NUMBER PERCENT
- ------- ------ ------- ------ -------
<S> <C> <C> <C> <C> <C>
The Shaar Group Ltd. 946,515(4)(5) 7.0% 2,595,734 0(4) *
Shaar Advisory Services Ltd. 108,518(4)(6) * 297,600 0(4) *
</TABLE>
- -----------------------
* Less than 1%.
(1) The persons named in the table, to the Company's knowledge, have sole
voting and investment power with respect to all shares shown as
beneficially owned by them, subject to community property laws where
applicable and the information contained in the footnotes hereunder.
(2) Determined in accordance with Rule 13-3(d) of the Exchange Act.
(3) Assumes all shares of Common Stock offered hereby are sold pursuant to
the registration statement of which the prospectus constitutes a part.
(4) The number of shares of Common Stock issuable upon conversion of
Convertible Debentures and in respect of interest in lieu of cash
issuable thereon will vary based upon the market value of the Company's
publicly-traded Common Stock prior to the date of conversion. For a
description of the method of determining the number of shares of Common
Stock issuable upon conversion of shares of Convertible Debentures, see
"Description of Securities - Convertible Debentures." Consequently, due
to the fluctuating conversion rate of the Convertible Debentures, the
number of shares of Common Stock that a holder of Convertible
Debentures may receive upon conversion or in lieu of cash interest may
exceed the number of shares of Common Stock such holder beneficially
owns as determined pursuant to Section 13-3(d) of the Exchange Act. For
purposes of the disclosure of Shares Beneficially Owned Prior to
Offering, it has been assumed (i) that the applicable conversion price
will be $1.9125 (calculated in accordance with the applicable terms of
the Convertible Debentures as of the date of issuance of the
Convertible Debentures on September 22, 1997), (ii) that all
Convertible Debentures beneficially owned by the Selling Stockholder
are converted into shares of Common Stock at such conversion price in
accordance with the applicable terms of the Convertible Debentures,
(iii) that all Debenture Warrants beneficially owned by the Selling
Stockholder have been exercised for shares of Common Stock and (iv)
that no shares of Common Stock have been issued to holders of
Convertible Debentures in lieu of cash interest thereon. For purposes
of the disclosure of Shares Beneficially Owned After the Offering, it
has been assumed that the applicable Selling Stockholder (x) has
converted all Convertible Debentures beneficially owned by it into
shares of Common Stock and has received no Common Stock issuable in
lieu of cash interest on such Convertible Debentures, (y) has exercised
all Debenture Warrants beneficially owned by it and (z) has sold all
such shares of Common Stock received by it.
(5) Consists of (i) 820,915 shares of Common Stock issuable upon conversion
of Conversion Debentures and (ii) 125,600 shares of Common Stock
issuable upon exercise of Debenture Warrants.
(6) Consists of (i) 94,118 shares of Common Stock issuable upon conversion
of Convertible Debentures and (ii) 14,400 shares of Common Stock
issuable upon exercise of Debenture Warrants.
-16-
<PAGE>
DESCRIPTION OF SECURITIES
The Company is currently authorized to issue 30,000,000 shares of
Common Stock, $.01 par value per share, of which 12,604,770 shares were issued
and outstanding on the date of this Prospectus, and 3,000,000 shares of
preferred stock, $.01 par value per share, of which 25,500 shares of Series A
Preferred Stock were issued and outstanding on the date of this Prospectus.
COMMON STOCK
Holders of shares of Common Stock are entitled to one vote per share on
all matters to be voted on by shareholders and do not have cumulative voting
rights. Subject to the rights of holders of outstanding shares of Series A
Preferred Stock and other holders of preferred stock of the Company, if any, the
holders of Common Stock are entitled to receive such dividends, if any, as may
be declared from time to time by the Board of Directors in its discretion from
funds legally available therefor, and upon liquidation or dissolution, are
entitled to receive all assets available for distribution to the shareholders.
The Common Stock has no preemptive or other subscription rights, and there are
no conversion rights of redemption or sinking fund provisions with respect to
such shares. All of the outstanding shares of Common Stock are fully paid and
nonassessable.
PREFERRED STOCK
The Board of Directors is authorized to issue the preferred stock in
one or more series and to fix the rights, preferences, privileges and
restrictions, including the dividend rights, conversion rights, voting rights,
rights and terms of redemption, redemption price or prices, liquidation
preferences and the number of shares constituting any series or the designations
of such series, without any further vote or action by the stockholders. The
issuance of preferred stock may have the effect of delaying, deferring or
preventing a change in control of the Company without further actions of the
stockholders. The issuance of preferred stock with voting and conversion rights
may adversely affect the voting power of the holders of Common Stock, including
the loss of voting control to others.
SERIES A PREFERRED STOCK
THE DESCRIPTION OF THE SERIES A PREFERRED STOCK PROVIDED BELOW IS
QUALIFIED IN ITS ENTIRETY BY THE RELATIVE RIGHTS, PREFERENCES, PRIVILEGES,
POWERS AND RESTRICTIONS OF THE SERIES A PREFERRED STOCK SET FORTH IN THE FORM OF
CERTIFICATE OF DESIGNATION FOR THE SERIES A PREFERRED STOCK INCLUDED IN EXHIBIT
4.2 TO THE COMPANY'S ANNUAL REPORT ON FORM 10-KSB FOR THE FISCAL YEAR ENDED
DECEMBER 31, 1996, WHICH IS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.
There are 25,500 shares of Series A Preferred Stock outstanding as of
the date of this Prospectus. Holders of Series A Preferred Stock have the right,
exercisable commencing May 29, 1997 and ending February 28, 1999, to convert
shares of Series A Preferred Stock into shares of Common Stock. The number of
shares of Common Stock issuable upon conversion of Series A Preferred Stock will
equal the number of shares of Series A Preferred Stock to be so converted
multiplied by a fraction, the numerator of which is 100 and the denominator of
which shall equal (a) $3.31875 in respect of conversions occurring on or before
June 27, 1997, (b) the lesser of (i) $3.31875 and (ii) the "current market
price" per share of Common Stock as of the applicable conversion date in respect
of conversions occurring from June 28, 1997 to and including August 26, 1997 and
(c) the lesser of (i) $3.31875 and (ii) 85% of the "current market price" per
share of Common Stock as of the applicable conversion date in respect of
conversions occurring after August 26, 1997, where "current market price" means,
with certain exceptions, the average of the closing bid prices of Common Stock
for the 10 consecutive trading days ending the last trading day before the
applicable conversion date. Each share of Series A Preferred Stock earns a
cumulative dividend payable in shares of Common Stock at a rate per share equal
to 7.0% of the original $100 purchase price per share of the Series A Preferred
Stock. Accrued stock dividends payable in respect of the Series A Preferred
Stock are payable at the time of conversion. Under certain circumstances, cash
is payable to holders of Series A Preferred Stock in lieu of Common Stock.
-16-
<PAGE>
The Series A Preferred Stock is redeemable by holders for $125 per
share in the event of (i) any reclassification or change of outstanding shares
of Common Stock issuable upon conversion of Series A Preferred Stock (other than
a change in par value), (ii) any consolidation or merger to which the Company is
a party other than a merger in which the Company is the continuing corporation
and which does not result in any reclassification of, or change (other than a
change in name, or par value, or from par value to no par value, or from no par
value to par value, or as a result of a subdivision or combination) in,
outstanding shares of Common Stock or (iii) any sale or conveyance of all or
substantially all of the property or business of the Company as an entirety. In
addition, upon the occurrence of a Change of Control, Series A Preferred Stock
holders may redeem their shares of Series A Preferred Stock for an amount per
share equal to the greater of (a) $125 and (b) the product of the aggregate
number of shares of Common Stock into which a share of Series A Preferred Stock
is otherwise convertible on the date preceding the change of control multiplied
by the then current market price of a share of Common Stock. A "Change in
Control" shall be deemed to have occurred at such time as either Douglas R. Eger
and Thomas M. Fitzgerald cease to be either a director or officer of the
Company.
6% CONVERTIBLE SUBORDINATED DEBENTURES
THE DESCRIPTION OF THE CONVERTIBLE DEBENTURES PROVIDED BELOW IS
QUALIFIED IN ITS ENTIRETY BY THE TERMS THEREOF SET FORTH IN THE FORM OF 6%
CONVERTIBLE SUBORDINATED DEBENTURE DUE SEPTEMBER 22, 2000 INCLUDED AS EXHIBIT
10.1 TO THE REGISTRATION STATEMENT ON FORM S-3 OF WHICH THIS PROSPECTUS
CONSTITUTES A PART.
On September 22, 1997, the Company consummated a private placement of
$1,750,000 principal amount of its 6% Convertible Subordinated Debentures due
September 22, 2000. The Convertible Debentures are convertible at the option of
holders from December 22, 1997 until maturity, subject to certain limitations,
into a number of shares of Common Stock equal to (i) the principal amount of the
Convertible Debenture being so converted divided by (ii) 75% of the market price
of the Common Stock as of the date of conversion. For purposes of any conversion
of Convertible Debentures, "market price" generally means the average of the
closing prices of the Common Stock for the five trading day period preceding the
applicable conversion date. The Convertible Debentures also earn interest at a
rate of 6.0% per annum that is payable by the Company, at the option of the
holders and subject to certain conditions, in share of its Common Stock at a
conversion rate generally equal to the average of the closing prices of the
Common Stock for the ten trading days preceding the applicable interest payment
date. Subject to certain limitations, the Convertible Debentures are subject to
mandatory redemption in full upon the occurrence of certain changes of control
events or upon an issuance of the Company's equity or debt resulting in gross
proceeds to the Company of at least $6,000,000, in each case at a premium above
the principal amount of Convertible Debentures so redeemed. The Convertible
Debentures are subject to optional redemption in whole or in part by the Company
at any time at a premium over the principal amount of Convertible Debentures so
redeemed. In connection with the sale of the Convertible Debentures, purchasers
thereof also received Debenture Warrants entitling the holders thereof to
purchase a total of 140,000 additional shares of Common Stock upon payment of an
exercise price of $2.80 per share, subject to certain adjustments. The Company
has granted the holders of the Convertible Debentures certain registration
rights in respect of the shares of Common Stock issuable upon conversion of the
Convertible Debentures, in lieu of cash interest on the Convertible Debentures
and upon exercise of the Debenture Warrants. The registration statement of which
this prospectus constitutes a part is intended to satisfy the Company's
registration obligations to the holders of the Convertible Debentures.
TRANSFER AGENT
The Company's transfer agent for its issued and outstanding Common
Stock is Harris Trust and Savings Bank, Houston, Texas.
PLAN OF DISTRIBUTION
The Common Stock offered hereby may be offered from time to time on the
AMEX or on any other securities exchange on which Common Stock is listed or in
privately negotiated transactions, at fixed prices that may be changed, at
market prices prevailing at the time of sale, at prices related to such
prevailing market prices or at
-18-
<PAGE>
privately negotiated prices. Selling Stockholders may effect such transactions
by selling such shares of Common Stock to or through one or more underwriters,
brokers, dealers or agents and all such underwriters, brokers, dealers and
agents may receive compensation in the form of discounts, concessions, or
commissions from stockholders and/or the purchasers of shares for whom such
broker-dealers may act as agent or to whom they sell as principal, or both
(which compensation as to a particular underwriter, broker, dealer or agent
might be in excess of customary commissions). The Company has agreed to
indemnify the Selling Stockholders against certain liabilities, including civil
liabilities under the Securities Act.
Any broker-dealer acquiring Common Stock offered hereby may sell such
securities either directly, in its normal market-making activities, through or
to other brokers on a principal or agency basis or to its customers. Any such
sales may be at prices then prevailing on the AMEX, at prices related to such
prevailing market prices or at negotiated prices to its customers or a
combination of such methods. The Selling Stockholders and any underwriters,
brokers, dealers or agents that act in connection with the sale might be deemed
to be "underwriters" within the meaning of Section 2(11) of the Securities Act
and any commissions received by them and any profit on the resale of securities
as principal may be deemed to be underwriting discounts and commissions under
the Securities Act. Any such commissions, as well as any applicable transfer
taxes, are payable by the applicable Selling Stockholder.
LEGAL MATTERS
The validity of the issuance of the securities being offered hereby has
been passed upon for the Company by Olshan Grundman Frome & Rosenzweig LLP, New
York, New York. Daniel J. Gallagher, an attorney at such firm, is the holder of
options to purchase 15,000 shares of Common Stock.
EXPERTS
The consolidated financial statements of Sheffield Pharmaceuticals,
Inc. and subsidiaries (a development stage enterprise) appearing in Sheffield
Pharmaceuticals, Inc.'s Annual Report (Form 10-KSB) for the years ended December
31, 1996 and 1995, have been audited by Ernst & Young LLP, independent auditors,
as set forth in their report thereon (which contains an explanatory paragraph
with respect to conditions that raise substantial doubt about the Company's
ability to continue as a going concern as further described in Note 1 to the
consolidated financial statements) included therein and incorporated herein by
reference. The consolidated financial statements of Sheffield Pharmaceuticals,
Inc. and subsidiary (a development stage enterprise) as of and for the year
ended December 31, 1994 incorporated by reference herein have been audited by
Ernst & Young LLP, independent auditors, as set forth in their report thereon
(which contains an explanatory paragraph with respect to conditions that raise
substantial doubt about the Company's ability to continue as a going concern as
further described in Note 7 to the consolidated financial statements) included
therein and incorporated herein by reference. Such consolidated financial
statements are, and audited financial statements to be included in subsequently
filed documents will be, incorporated herein in reliance upon the reports of
Ernst & Young LLP pertaining to such financial statements (to the extent covered
by consents filed with the Securities and Exchange Commission) given upon the
authority of such firm as experts in accounting and auditing.
The consolidated financial statements of Sheffield Pharmaceuticals,
Inc. and subsidiary (a development stage enterprise) as of December 31, 1993 and
for the period from October 17, 1986 (inception) to December 31, 1993 and the
years ended December 31, 1992 and 1993 have been incorporated by reference
herein and in the registration statement of which this Prospectus constitutes a
part in reliance upon the report of KPMG Peat Marwick LLP, independent certified
public accountants, incorporated by reference herein, and upon the authority of
said firm as experts in accounting and auditing.
The report of KPMG Peat Marwick LLP covering the December 31, 1993
consolidated financial statements contains an explanatory paragraph that states
that the Company's recurring losses and net deficit position raise substantial
doubt about its ability to continue as a going concern. The consolidated
financial statements do not include any adjustments that might result from the
outcome of that uncertainty.
-19-
<PAGE>
ADDITIONAL INFORMATION
The Company has filed with the Commission a Registration Statement on
Form S-3 under the Securities Act (the "Registration Statement") with respect to
certain of the shares of Common Stock offered hereby. For further information
with respect to the Company and the securities offered hereby, reference is made
to the Registration Statement. Statements contained in this Prospectus as to the
contents of any contract or other document are not necessarily complete, and in
each instance, reference is made to the copy of such contract or document filed
as an exhibit to the Registration Statement, each such statement being qualified
in all respects by such reference.
-20-
